The major cause of death due to cancer is its metastatic deposit in numerous tissues and organs. The metastatic process requires the migration of malignant cells from primary sites to distant environments. Even for tumors initially spreading through lymphatic vessels, hematogenous transport is the most common metastatic pathway. The detachment of cancer cells from a primary tumor into the blood stream is called epithelial-mesenchymal transition (EMT). As these cells circulate further in the bloodstream they are known as circulating tumor cells (CTCs). The CTC population is highly resilient, enabling the cells to colonize a foreign microenvironment. Alternatively, cancer stem cells (CSCs) may arise from differentiated cancer cells through EMT and an embryonic transdifferentiation process. The presence of CTCs/CSCs in blood seems to be a determining factor of metastasis. This paper reviews various methods of clinical cancer detection as well as the biology and molecular characterization of CTCs/CSCs. Our goal was to summarize clinical studies which used CTC/CSCs for prognosis in patients with breast, colorectal, prostate, lung, ovarian, and bladder cancer.

Department of Tumor Biology 3rd Faculty of Medicine Charles University Prague Czech Republic

Circulating Tumor Cells, Circulating Tumor DNA and Other Blood-based Prognostic Scores in Pancreatic Ductal Adenocarcinoma - Mini-Review

Molecular characterization and heterogeneity of circulating tumor cells in breast cancer

Circulating Tumor Cells as an Auxiliary Diagnostic Tool in Surgery

The added value of circulating tumor cells examination in ovarian cancer staging

Isolation, primary culture, morphological and molecular characterization of circulating tumor cells in gynecological cancers

Circulating tumor cells in pancreatic cancer patients: enrichment and cultivation

In vitro culturing of viable circulating tumor cells of urinary bladder cancer